Ultragenyx Pharmaceutical
RARE
174 hedge funds and large institutions have $2.8B invested in Ultragenyx Pharmaceutical in 2016 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 69 increasing their positions, 55 reducing their positions, and 15 closing their positions.
132% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $6.15M
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
55% more capital invested
Capital invested by funds: $1.81B → $2.8B (+$989M)
25% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 55
7% more funds holding
Funds holding: 162 → 174 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$31.5M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$30.7M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$25.1M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$17.2M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$39.1M |
| 2 |
Millennium Management
New York
|
-$28.8M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$11.5M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$11.2M |
| 5 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
-$6.84M |
RARE Hedge Fund Activity: Q3 2016 in Review
174 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2016, worth a combined $2.8B — up 55% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RARE positions and 15 closed out — a net gain of 13 holders — while 69 added to existing stakes and 55 trimmed.
The largest buyer was Capital Guardian Trust, opening a new position worth an estimated $31.5M. The largest seller was Wells Fargo, cutting an estimated $39.1M.
- 174 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2016, up from 162 in Q2 2016.
- Funds reported $2.8B of Ultragenyx Pharmaceutical stock for Q3 2016, up 55% quarter-over-quarter.
- 28 funds opened new Ultragenyx Pharmaceutical positions in Q3 2016 and 15 closed out, a net change of +13 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2016 was Capital Guardian Trust, an estimated $31.5M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2016 was Wells Fargo, an estimated $39.1M sold.
Based on aggregated 13F filings for Q3 2016.